Literature DB >> 19891997

Generation and biological assessment of recombinant avian metapneumovirus subgroup C (aMPV-C) viruses containing different length of the G gene.

Qingzhong Yu1, Carlos Estevez, Minxun Song, Darrell Kapczynski, Laszlo Zsak.   

Abstract

Genetic variation in length of the G gene among different avian metapneumovirus subgroup C (aMPV-C) isolates has been reported. However, its biological significance in virus replication, pathogenicity and immunity is unknown. In this study, we developed a reverse genetics system for aMPV-C and generated two Colorado (CO) strain-based recombinant viruses containing either the full-length G gene derived from a Canadian goose isolate or a C-terminally truncated G gene of the CO strain. The truncated short G (sG) gene encoded 252 amino acids (aa), which is 333 aa shorter than the full-length G (585 aa). The biological properties of these two recombinant G variants were assessed in Vero cells and in specific-pathogen-free (SPF) turkeys. In Vero cells, the short G variant displayed a similar level of growth dynamics and virus titers as the parental aMPV-CO strain, whereas the full-length G variant replicated less efficiently than the sG variant during the first 72 h post-infection. Both of the G variants induced typical cytopathic effects (CPE) that were indistinguishable from those seen with the parental aMPV-CO infection. In SPF turkeys, both of the G variants were attenuated and caused little or no disease signs, but the full-length G variant appeared to grow more readily in tracheal tissue than the sG variant during the first 5 days post-infection. Both G variants were immunogenic and induced a slightly different level of antibody response. These results demonstrated that the large portion (333 aa) of the extracellular domain of the viral attachment protein is not essential for virus viability in vitro and in vivo, but may play a role in enhancing virus attachment specificity and immunity in a natural host. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891997     DOI: 10.1016/j.virusres.2009.10.021

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

1.  Deletion of the M2-2 gene from avian metapneumovirus subgroup C impairs virus replication and immunogenicity in Turkeys.

Authors:  Qingzhong Yu; Carlos N Estevez; Jason P Roth; Haixia Hu; Laszlo Zsak
Journal:  Virus Genes       Date:  2011-02-02       Impact factor: 2.332

2.  Methyltransferase-defective avian metapneumovirus vaccines provide complete protection against challenge with the homologous Colorado strain and the heterologous Minnesota strain.

Authors:  Jing Sun; Yongwei Wei; Abdul Rauf; Yu Zhang; Yuanmei Ma; Xiaodong Zhang; Konstantin Shilo; Qingzhong Yu; Y M Saif; Xingmeng Lu; Lian Yu; Jianrong Li
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 3.  Zoonotic Origins of Human Metapneumovirus: A Journey from Birds to Humans.

Authors:  Sonja T Jesse; Martin Ludlow; Albert D M E Osterhaus
Journal:  Viruses       Date:  2022-03-25       Impact factor: 5.818

4.  Engineered Newcastle disease virus expressing the F and G proteins of AMPV-C confers protection against challenges in turkeys.

Authors:  Haixia Hu; Jason P Roth; Laszlo Zsak; Qingzhong Yu
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

5.  Complete Genome Sequence of an Avian Metapneumovirus Subtype B Strain from Hungary.

Authors:  Iryna V Goraichuk; Darrell R Kapczynski; Bruce S Seal; David L Suarez
Journal:  Microbiol Resour Announc       Date:  2020-05-07

6.  The pathogenicity of avian metapneumovirus subtype C wild bird isolates in domestic turkeys.

Authors:  Ra Mi Cha; Qingzhong Yu; Laszlo Zsak
Journal:  Virol J       Date:  2013-01-30       Impact factor: 4.099

7.  Structural insights into the human metapneumovirus glycoprotein ectodomain.

Authors:  Cedric Leyrat; Guido C Paesen; James Charleston; Max Renner; Jonathan M Grimes
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.